diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5478diaendo-5478Research ArticleСтатьиArticlesПрименение Триметазидина? при ишемической болезни сердца в сочетании с сахарным диабетомPrimenenie Trimetazidina? pri ishemicheskoy bolezni serdtsa v sochetanii s sakharnym diabetomФедоткинаЮ АFedotkinaYu A-ДобровольскийА ВDobrovol'skiyA V-ТитаеваЕ ВTitaevaE V-ШубинаТ АShubinaT A-ПанченкоЕ ПPanchenkoE P-Институт клинической кардиологии им. А.Л. Мясникова РКНПК МЗ РФ, Москва20021506200252№2 (2002)4855Copyright © Федоткина Ю.А., Добровольский А.В., Титаева Е.В., Шубина Т.А., Панченко Е.П., 20022002Федоткина Ю.А., Добровольский А.В., Титаева Е.В., Шубина Т.А., Панченко Е.П.Fedotkina Y.A., Dobrovol'skiy A.V., Titaeva E.V., Shubina T.A., Panchenko E.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5478

Цель: сравнительное изучние антиишемического действия триметазидина у больных стабильной стенокардией без и с нарушениями углеводного обмена, а также исследование показателей гемостаза с оценкой эффектов изучаемого препарата. Материалы и методы: В исследование включено 40 больных ИБС и стабильной стенокардией II-III ФК, из них 37 мужчин и 3 женщины, средний возраст которых составил 56,7 ?1,95 лет. Верификация диагноза ИБС проводилась с помощью ВЭМ-пробы, у 21 больного в сочетании со сцинтиграфией миокарда с радиофармпрепаратом МИБИ (метоксиизобутилизометрил, Технетрил, Россия), выполненной на максимуме ВЭМ пробы и в покое; у 15 ? больных с помощью коронароангиографии; у 21 ? больного на основании указаний на перенесенный инфаркт миокарда, подтверждённых результатами ЭКГ. Результаты: Через 2 мес. терапии ТМЗ в обеих группах уменьшилось число больных с наличием депрессии сегмента ST на максимуме ВЭМ-пробы: в группе 1 - на 40%. В группе II (ИБС+НУО) отмечалось уве-личение величины выполняемой работы на 22%. одной из групп. В обеих группах больные отмечали улучшение качества жизни: уменьшение количества приступов стенокардии и принимаемого нитроглицерина, в группе I ? соответственно на 30% и 13%, в группе II ? на 43% и 51%.

ишемическая болезнь сердцасцинтиграфия миокардадепрессия сегмента STReferencesБалаболкин М., Клебанова Е., Креминская В. Кардиология 2000; 10:74-87.Балаболкин М., Клебанова Е., Креминская В. Кардиология 2000; 10:74-87.Панченко Е., Добровольский А.Тромбозы в кардиологии. Механизмы развития и возможности терапии. Изд. «Спорт и культура.», 1 999.Панченко Е., Добровольский А.Тромбозы в кардиологии. Механизмы развития и возможности терапии. Изд. «Спорт и культура.», 1 999.Akhras F,Jackson G. Lancet. 1991; 338: 1036-1039.Akhras F,Jackson G. Lancet. 1991; 338: 1036-1039.Al-Zahrani H, Lowe G, Douglas J, et al. Clin Hemorheol. 1992; 1 2:867-872.Al-Zahrani H, Lowe G, Douglas J, et al. Clin Hemorheol. 1992; 1 2:867-872.American Diabetes Association. Diabetes Care. 1993;16:828-834.American Diabetes Association. Diabetes Care. 1993;16:828-834.Brownlee M,Cerami A, Vlassara H. Advanced giycosylation end products in tissue and biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-21.Brownlee M,Cerami A, Vlassara H. Advanced giycosylation end products in tissue and biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-21.Catto A., Carter A., Barrett J. Von Willebrand factor and factor VII: С in acute cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb. Haemost. 1 997;77(6):1 1 04-1 1 08.Catto A., Carter A., Barrett J. Von Willebrand factor and factor VII: С in acute cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb. Haemost. 1 997;77(6):1 1 04-1 1 08.Cortellaro М., Boschetti C., Zanussi C. The PLAT study: haemostatic function in relation to atherothrombotic ischemic events in vascular disease petients. Principal results. Arterioscler. Thromb. 1992; 12(9): 1063-1070.Cortellaro М., Boschetti C., Zanussi C. The PLAT study: haemostatic function in relation to atherothrombotic ischemic events in vascular disease petients. Principal results. Arterioscler. Thromb. 1992; 12(9): 1063-1070.Dalla-Volta S., Maraglino G., Della-Valentina P. Et.al. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc. Drugs Ther., 1990,4, 853-859.Dalla-Volta S., Maraglino G., Della-Valentina P. Et.al. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc. Drugs Ther., 1990,4, 853-859.David M Nathan,James Meigs, Daniel E Singer. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is.. or is it? Lancet 1 997;350(suppl I): 4-9.David M Nathan,James Meigs, Daniel E Singer. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is.. or is it? Lancet 1 997;350(suppl I): 4-9.David S. H., Fernando Ovalle. Diabetes as a Risk Factor for Ischemic Heart Disease. Clin Rev Spring:88-92, 2000. (c) 2000 Southern Medical Association.David S. H., Fernando Ovalle. Diabetes as a Risk Factor for Ischemic Heart Disease. Clin Rev Spring:88-92, 2000. (c) 2000 Southern Medical Association.Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina. Compison with propranolol in patients with stable angina. TEMS study. Br J Clin Pharmacol. 1 994; 37:279-288.Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina. Compison with propranolol in patients with stable angina. TEMS study. Br J Clin Pharmacol. 1 994; 37:279-288.Fantini E., Demaison L., Sentex E., et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J. Mol. Cell. Cardiol. 1 994; 26: 949-958.Fantini E., Demaison L., Sentex E., et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J. Mol. Cell. Cardiol. 1 994; 26: 949-958.Folsom A, Wu K, Rosamond W. Prospective study of hemostatic factors and incidence of coronary heart disease: The atherosclerosis risk in communities (ARIC) study. Circulation. 1 997;96:1 102-1 108.Folsom A, Wu K, Rosamond W. Prospective study of hemostatic factors and incidence of coronary heart disease: The atherosclerosis risk in communities (ARIC) study. Circulation. 1 997;96:1 102-1 108.Fowkes F, Lowe G, Housley E, et al. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk factors of coronary heart disease. Lancet. 1993;342:84-86.Fowkes F, Lowe G, Housley E, et al. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk factors of coronary heart disease. Lancet. 1993;342:84-86.Fox KM, Mulcahy D, Findlay I, et al. The Total Ischaemic Burden European Trial (TIBET). Eur Heart J. 1996; 17:96-103Fox KM, Mulcahy D, Findlay I, et al. The Total Ischaemic Burden European Trial (TIBET). Eur Heart J. 1996; 17:96-103Jensen T. Increased plasma concentration of von Willibrand factor in insulin dependent diabetic with incipient nephropathy. Br Med J. 1989; 298:27-28.Jensen T. Increased plasma concentration of von Willibrand factor in insulin dependent diabetic with incipient nephropathy. Br Med J. 1989; 298:27-28.Kannel W, DAgostino R, Wilson P. Diabetes,fibrinogen,and risk of cardiovascular disease. The Farmingham experience. Am Heart J., 1990;120:672-676.Kannel W, DAgostino R, Wilson P. Diabetes,fibrinogen,and risk of cardiovascular disease. The Farmingham experience. Am Heart J., 1990;120:672-676.Kantor P., Kozak R., Lopschuk G. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation нокардией и нарушениями углеводного обмена снижает содержание фактора фон Виллебранда. ату pa by inhibiting mitochondrial Long-Chain-Ketoacyl-Coenzym A Thiolase. Circ.Res., 2000, 86,580-588.Kantor P., Kozak R., Lopschuk G. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation нокардией и нарушениями углеводного обмена снижает содержание фактора фон Виллебранда. ату pa by inhibiting mitochondrial Long-Chain-Ketoacyl-Coenzym A Thiolase. Circ.Res., 2000, 86,580-588.Kario К et al. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vase Biol. 1 995; 15:11141 120.Kario К et al. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vase Biol. 1 995; 15:11141 120.Meigs JB, Singer DE, Sullivan IM, et al. Metabolic control and prevalent cardiovascular disease in non-insulin dependent dibetes mellitus (NIDDM): the NIDDM patient outcomes research group. Am J Med 1997; 102: 38-47.Meigs JB, Singer DE, Sullivan IM, et al. Metabolic control and prevalent cardiovascular disease in non-insulin dependent dibetes mellitus (NIDDM): the NIDDM patient outcomes research group. Am J Med 1997; 102: 38-47.Nordt T, Schneider D, Sobel B. Augmetation of the synthesis of plasminogen activator inhibitor type-1 by precursors of unsulin: a potential risk factor for vascular disease. Circulation. 1 994; 89:321 -330.Nordt T, Schneider D, Sobel B. Augmetation of the synthesis of plasminogen activator inhibitor type-1 by precursors of unsulin: a potential risk factor for vascular disease. Circulation. 1 994; 89:321 -330.Opie LH. The Heart: Physiology and Metabolism. New York, NY: Raven Press; 1991:208-276.Opie LH. The Heart: Physiology and Metabolism. New York, NY: Raven Press; 1991:208-276.Ridker P, Hennekens C,et al. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and risk of future myocardial infarction among apparently health men. Circulation. 1 994;90:2236-2240.Ridker P, Hennekens C,et al. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and risk of future myocardial infarction among apparently health men. Circulation. 1 994;90:2236-2240.Savonitto S, Ardissino D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with sta- bleangina pectoris. J Am Coll Cardiol. 1 996; 27:31 1-316Savonitto S, Ardissino D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with sta- bleangina pectoris. J Am Coll Cardiol. 1 996; 27:31 1-316Sentex E., Sergiel JP., Lucien A., et al. Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol. Cell. Biochem. 1997; 175: 153-162.Sentex E., Sergiel JP., Lucien A., et al. Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol. Cell. Biochem. 1997; 175: 153-162.Stanley WC, Lopaschuk GD, McCormarck JG. Regulation of substrate metabolism in the diabetic heart. Cardiovas Res. 1 997; 34:25-33Stanley WC, Lopaschuk GD, McCormarck JG. Regulation of substrate metabolism in the diabetic heart. Cardiovas Res. 1 997; 34:25-33Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. Cardiovasc Res. 1997;33:243-257.Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. Cardiovasc Res. 1997;33:243-257.Stehouwer C, Nauta J, Zeldenrust G. Urinary albumin excretion, cardiovascular diasease, and endotelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1 992; 340:31 9-323.Stehouwer C, Nauta J, Zeldenrust G. Urinary albumin excretion, cardiovascular diasease, and endotelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1 992; 340:31 9-323.Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. J Am Coil Cardiol. 1989;14:49-57.Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. J Am Coil Cardiol. 1989;14:49-57.Szwed H., Pachocki R., Donzal-Bochelska M. Et.al. The anti-ischaemic affects and tolerability of trimetazidine in coronary diabetic patients: a substudy from TRIMPOL-1. Cardiovasc. Drug Ther., In press.Szwed H., Pachocki R., Donzal-Bochelska M. Et.al. The anti-ischaemic affects and tolerability of trimetazidine in coronary diabetic patients: a substudy from TRIMPOL-1. Cardiovasc. Drug Ther., In press.Taegtmeyer H. Energy metabolism in the heart. Curr Probi Cardiol. 1994; 19:59-1 13.)Taegtmeyer H. Energy metabolism in the heart. Curr Probi Cardiol. 1994; 19:59-1 13.)Thompson S., Kienast J., Pyke S. Haemostatic factors and risk of myicar- dial infarction or sudden death in patients with angina pectoris. N. Engl. J. Med. 1995; 332:635-641.Thompson S., Kienast J., Pyke S. Haemostatic factors and risk of myicar- dial infarction or sudden death in patients with angina pectoris. N. Engl. J. Med. 1995; 332:635-641.World Health Organization (WHO). Prevention of Diabetes Mellitus. In: WHO Technical Report Series N 844 Geneva: WHO, 1 994.World Health Organization (WHO). Prevention of Diabetes Mellitus. In: WHO Technical Report Series N 844 Geneva: WHO, 1 994.

The authors declare that there are no conflicts of interest present.